Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years

Medicine and Dentistry

• Patient 100%
• Proteinase Inhibitor 50%
• Antiretroviral Therapy 50%
• Nonnucleoside Reverse Transcriptase Inhibitor 40%
• Inpatient 40%
• Human Immunodeficiency Virus 30%
• Life Expectancy 20%
• Drug 20%
• Chemotherapeutic Agent 20%
• Combination Therapy 10%
• Population 10%
• Cohort Effect 10%
• Ritonavir 10%
• Incidence 10%

Nursing and Health Professions

• Antiretroviral Therapy 50%
• Nonnucleoside Reverse Transcriptase Inhibitor 40%
• Confidence Interval 20%
• Life Expectancy 20%
• Drug 20%
• Epidemiology 10%
• Combination Therapy 10%
• Population 10%
• Time 10%
• Incidence 10%
• Ritonavir 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Proteinase Inhibitor 50%
• Nonnucleoside Reverse Transcriptase Inhibitor 40%
• HIV 30%
• Life Expectancy 20%
• Drug 20%
• Rose 10%
• Epidemiology 10%
• Ritonavir 10%
• Incidence 10%